{
  "docId": "019de072-4935-7342-8528-4e6eca3fe5c7",
  "docSlug": "31ea92baba83669e6443d115d329d67b",
  "documentTitle": "AstraZeneca | Investor Presentation Deck | 53 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 53,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide uses a three-column layout to categorize performance metrics and achievements.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-4935-7342-8528-4e6eca3fe5c7/6",
  "deckHref": "/decks/019de072-4935-7342-8528-4e6eca3fe5c7",
  "deckJsonHref": "/decks/019de072-4935-7342-8528-4e6eca3fe5c7.json",
  "deckAnchorHref": "/decks/019de072-4935-7342-8528-4e6eca3fe5c7#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.94,
        "x": 0.03,
        "y": 0.8
      },
      "kind": "callout",
      "text": "FY 2021: Total Revenue $37.4bn (+38%) | Core EPS of $5.29 (+37%)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df2bb2fa-ca61-47a3-9701-2b8e7a1c0234",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.03,
        "y": 0.91
      },
      "kind": "disclaimer",
      "text": "Absolute values at actual exchange rates; changes at constant exchange rates (CER)...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d97a4861-48ba-40cb-b3a9-57f05c3714e4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.31,
        "x": 0.35,
        "y": 0.23
      },
      "kind": "list",
      "text": "Broad-based performance: Delivering value to patients. Oncology $13.7bn (+17%), BioPharmaceuticals (CVRM $8.0bn, Resp $6.0bn, Other $2.5bn, COVID $4.1bn), Rare Disease $3.1bn (+9%).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1eca19e7-9e7d-43b9-94d5-a852fb3fc5cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.31,
        "x": 0.03,
        "y": 0.23
      },
      "kind": "list",
      "text": "Robust growth: Exceeded FY 2021 revenue guidance. Total Revenue $37.4bn (+38%), $33.4bn (+23%) excluding Vaxzevria, $35.2bn (+30%) including Q4 Vaxzevria. Core EPS $5.29 (+37%).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40b6ec48-85de-4df2-a8a7-9aa87c47da86",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.31,
        "x": 0.67,
        "y": 0.23
      },
      "kind": "list",
      "text": "Science-led innovation: Strong Q4 2021 performance. Tezspire US approval, Evusheld US EUA, Lynparza US Priority Review, Saphnelo EU CHMP recommendation, Ultomiris US Priority Review.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4acb6d66-4b67-48cd-957e-4af92ad8108d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.53,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Continuing to deliver on our strategic objectives",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d039b42-348b-4fb3-9838-ebc555fa2e17",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.53,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Full year and Q4 2021: key updates",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5cf0b13e-934b-42a7-aa02-2b7f85cdf9b7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 6,
      "beatId": "ece83bc0-2007-47be-ac7d-f82241b4b160",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Key Takeaways",
      "beatSlug": null,
      "evidence": "The deck presents key takeaways and messages, highlighting industry-leading growth and innovation",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}